GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLMW) » Definitions » Minority Interest

Apollomics (Apollomics) Minority Interest : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Apollomics Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Apollomics's minority interest for the quarter that ended in Dec. 2023 was $0.00 Mil.


Apollomics Minority Interest Historical Data

The historical data trend for Apollomics's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics Minority Interest Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Minority Interest
- - - -

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Minority Interest Get a 7-Day Free Trial - - - - -

Apollomics Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.


Apollomics (Apollomics) Business Description

Traded in Other Exchanges
Address
989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an innovative clinical-stage biotechnology company. It is is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. It has a pipeline of 9 drug candidates across multiple programs, 6 of which are in the clinical stage of development.